192 related articles for article (PubMed ID: 23426097)
21. Temperament and character in subjects with obsessive-compulsive disorder.
Kim SJ; Kang JI; Kim CH
Compr Psychiatry; 2009; 50(6):567-72. PubMed ID: 19840596
[TBL] [Abstract][Full Text] [Related]
22. Factor analysis of the Yale-Brown Obsessive Compulsive Scale in a family study of obsessive-compulsive disorder.
Cullen B; Brown CH; Riddle MA; Grados M; Bienvenu OJ; Hoehn-Saric R; Shugart YY; Liang KY; Samuels J; Nestadt G
Depress Anxiety; 2007; 24(2):130-8. PubMed ID: 16892417
[TBL] [Abstract][Full Text] [Related]
23. High-dose escitalopram for the treatment of obsessive-compulsive disorder.
Rabinowitz I; Baruch Y; Barak Y
Int Clin Psychopharmacol; 2008 Jan; 23(1):49-53. PubMed ID: 18090508
[TBL] [Abstract][Full Text] [Related]
24. Measuring obsessive-compulsive symptoms: Padua Inventory-Revised vs. Yale-Brown Obsessive Compulsive Scale.
Anholt GE; van Oppen P; Emmelkamp PM; Cath DC; Smit JH; van Dyck R; van Balkom AJ
J Anxiety Disord; 2009 Aug; 23(6):830-5. PubMed ID: 19443176
[TBL] [Abstract][Full Text] [Related]
25. Rage attacks in pediatric obsessive-compulsive disorder: phenomenology and clinical correlates.
Storch EA; Jones AM; Lack CW; Ale CM; Sulkowski ML; Lewin AB; De Nadai AS; Murphy TK
J Am Acad Child Adolesc Psychiatry; 2012 Jun; 51(6):582-92. PubMed ID: 22632618
[TBL] [Abstract][Full Text] [Related]
26. Clinical correlates of social adjustment in patients with obsessive-compulsive disorder.
Rosa AC; Diniz JB; Fossaluza V; Torres AR; Fontenelle LF; De Mathis AS; da Conceição Rosário M; Miguel EC; Shavitt RG
J Psychiatr Res; 2012 Oct; 46(10):1286-92. PubMed ID: 22800713
[TBL] [Abstract][Full Text] [Related]
27. Obsessive-compulsive disorder and migraine with medication-overuse headache.
Cupini LM; De Murtas M; Costa C; Mancini M; Eusebi P; Sarchielli P; Calabresi P
Headache; 2009 Jul; 49(7):1005-13. PubMed ID: 19496831
[TBL] [Abstract][Full Text] [Related]
28. The impact of symptom dimensions on outcome for exposure and ritual prevention therapy in obsessive-compulsive disorder.
Williams MT; Farris SG; Turkheimer EN; Franklin ME; Simpson HB; Liebowitz M; Foa EB
J Anxiety Disord; 2014 Aug; 28(6):553-8. PubMed ID: 24983796
[TBL] [Abstract][Full Text] [Related]
29. Convergent and discriminant validity of the Yale-Brown Obsessive-Compulsive Scale Symptom Checklist.
Mataix-Cols D; Fullana MA; Alonso P; Menchón JM; Vallejo J
Psychother Psychosom; 2004; 73(3):190-6. PubMed ID: 15031592
[TBL] [Abstract][Full Text] [Related]
30. [Validation of a scale for responsibility (Salkovskis Responsibility Scale)].
Bouvard M; Robbe-Grillet P; Milliery M; Pham S; Amireche S; Fanget F; Guerin J; Cottraux J
Encephale; 2001; 27(3):229-37. PubMed ID: 11488253
[TBL] [Abstract][Full Text] [Related]
31. Factor analysis of symptom subtypes of obsessive compulsive disorder and their relation to personality and tic disorders.
Baer L
J Clin Psychiatry; 1994 Mar; 55 Suppl():18-23. PubMed ID: 8077163
[TBL] [Abstract][Full Text] [Related]
32. Bulimia nervosa with and without obsessive-compulsive syndromes.
Albert U; Venturello S; Maina G; Ravizza L; Bogetto F
Compr Psychiatry; 2001; 42(6):456-60. PubMed ID: 11704935
[TBL] [Abstract][Full Text] [Related]
33. The Yale-Brown Obsessive Compulsive Scale: factor analysis, construct validity, and suggestions for refinement.
Deacon BJ; Abramowitz JS
J Anxiety Disord; 2005; 19(5):573-85. PubMed ID: 15749574
[TBL] [Abstract][Full Text] [Related]
34. Principal components analysis of obsessive-compulsive disorder symptoms in children and adolescents.
Stewart SE; Rosario MC; Brown TA; Carter AS; Leckman JF; Sukhodolsky D; Katsovitch L; King R; Geller D; Pauls DL
Biol Psychiatry; 2007 Feb; 61(3):285-91. PubMed ID: 17161383
[TBL] [Abstract][Full Text] [Related]
35. Obsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol.
Sa AR; Hounie AG; Sampaio AS; Arrais J; Miguel EC; Elkis H
Compr Psychiatry; 2009; 50(5):437-42. PubMed ID: 19683614
[TBL] [Abstract][Full Text] [Related]
36. [Efficacy assessment of fluoxetine treatment of outpatients with obsessive-compulsive disorder: a preliminary report].
Wandzel L
Psychiatr Pol; 1997; 31(4):429-35. PubMed ID: 9527686
[TBL] [Abstract][Full Text] [Related]
37. Treatment response, symptom remission, and wellness in obsessive-compulsive disorder.
Farris SG; McLean CP; Van Meter PE; Simpson HB; Foa EB
J Clin Psychiatry; 2013 Jul; 74(7):685-90. PubMed ID: 23945445
[TBL] [Abstract][Full Text] [Related]
38. L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: A randomized double-blind study.
Arabzadeh S; Shahhossenie M; Mesgarpour B; Rezaei F; Shalbafan MR; Ghiasi Z; Akhondzadeh S
Hum Psychopharmacol; 2017 Jul; 32(4):. PubMed ID: 28485008
[TBL] [Abstract][Full Text] [Related]
39. New treatment options for OCD.
Fineberg NA
Int J Psychiatry Clin Pract; 2007; 11 Suppl 2():24-30. PubMed ID: 24926869
[TBL] [Abstract][Full Text] [Related]
40. Cerebral glucose metabolism in obsessive-compulsive hoarding.
Saxena S; Brody AL; Maidment KM; Smith EC; Zohrabi N; Katz E; Baker SK; Baxter LR
Am J Psychiatry; 2004 Jun; 161(6):1038-48. PubMed ID: 15169692
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
